Emerging role of dual biologic therapy for the treatment of inflammatory bowel disease

作     者：Matthew D McCormack Natasha A Wahedna David Aldulaimi Peter Hawker 

作者机构：Department of GastroenterologySouth Warwickshire NHS Foundation TrustWarwick HospitalWarwick CV345BWUnited Kingdom 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2023年第11卷第12期

页      面：2621-2630页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Dual biologic therapy Inflammatory bowel disease Crohn’s disease Ulcerative colitis Combination therapy Biologic safety 

摘      要：Biologic agents have now been used in the management of inflammatory bowel disease(IBD)for many years where experience,expertise and confidence in their use has developed over *** the United Kingdom,there are well established guidelines and recommendations for both single agent biologic treatments,and with combination therapy of a biologic agent with a small molecule agent in maintenance *** recent times,there has been increasing interest and experience using dual biologic therapy(DBT)in IBD,primarily in difficult to treat and refractory cases with high disease ***,published data on use,experience and safety profiles is limited and large-scale studies remain low in number in this developing *** therefore aim to present a summary and review of the available published data in this area to help us better understand the emerging role of DBT in IBD.